Pfizer announces two-in-one vaccine for Covid AND flu

Pfizer is testing a new two-in-one vaccine targeting both Covid and the flu, while uptake is slow for the booster shot.

The first patient was vaccinated with the vaccine this week in early clinical trials, with a total of 180 patients expected to receive the dose.

Using mRNA technology made popular during the Covid pandemic, the shot targets BA.4 and BA.5 variants, as well as four strains of influenza.

Vaccine maker Moderna is also testing a vaccine against Covid and flu, as well as one against those viruses and RSV — behind America’s winter wave. None are expected to be ready for this year’s flu season.

Uptake of the updated bivalent booster vaccine is lagging in the US with only a handful of eligible Americans coming forward.

The pharmaceutical giant said the first patient received a dose this week in the early-stage trials, which will last six months (file photo).

The pharmaceutical giant said the first patient received a dose this week in the early-stage trials, which will last six months (file photo).

The pharmaceutical giant said the first patient received a dose this week in the early-stage trials, which will last six months (file photo).

The graph above shows the number of positive RSV virus tests by date in the United States. It shows they are now at their highest level since 2020, before the pandemic started. The data comes from the Centers for Disease Control and Prevention

The graph above shows the number of positive RSV virus tests by date in the United States. It shows they are now at their highest level since 2020, before the pandemic started. The data comes from the Centers for Disease Control and Prevention

The graph above shows the number of positive RSV virus tests by date in the United States. It shows they are now at their highest level since 2020, before the pandemic started. The data comes from the Centers for Disease Control and Prevention

Pfizer announced that the first patient in its Phase 1 trials — its earliest clinical trials — was given an injection this week.

These tests are designed to ensure the vaccine is safe and effective, but the new vaccine will need to go through more testing before it can be rolled out nationwide.

The study recruited 180 people in the US between the ages of 18 and 64 and will be followed for six months.

Annaliesa Anderson, chief scientific officer in vaccines research and development at Pfizer, said the mRNA technology is “well suited” to targeting other viruses.

“Pfizer is extremely proud of our continued work to explore its potential to protect against influenza and Covid in a combination vaccine,” she said.

‘We believe [this] could simplify vaccination practices against these two respiratory pathogens and potentially lead to better vaccine uptake for both diseases.

“Even with existing seasonal influenza vaccines, the burden of this virus is severe worldwide, causing thousands of deaths and hospitalizations each year.”

Currently, the flu vaccine is rolled out every year to boost immunity to the virus in those who are more susceptible.

Some scientists suggest that Covid vaccines are also needed every year as the immunity they induce wears off over time.

So far, health officials have suggested people should get their flu and Covid shots at the same time, with one in each arm.

But testing of Pfizer’s new vaccine is trying to narrow this down to just one shot by grouping the two together.

Pfizer’s new 80% effective RSV vaccine brings hope to overwhelmed children’s hospitals

Pfizer has announced that its experimental RSV vaccine is highly effective – a ray of hope for parents and doctors.

The pharmaceutical giant announced that its injection may reduce the risk of hospitalization in infants aged up to six months infected with the seasonal virus.

If approved, it would be the first vaccine against RSV, killing between 100 and 500 children under the age of five each year and hospitalizing about 58,000.

That could prove a lifeline for hospitals, which are currently overwhelmed with unusually high cases of the virus – which has been blamed on lockdowns aimed at suppressing child immunity.

The vaccine is given to pregnant women during the late second to third trimester of their pregnancy. Vaccination during pregnancy allows the antibodies to cross to the placenta, protecting the fetus.

Pfizer’s study involved 7,400 pregnant women in 18 countries, who received either one dose of the experimental vaccine or a placebo.

Pfizer expects to complete its application for approval by the Food and Drug Administration by the end of 2022, and potentially grant a federal approval before the next respiratory infection season begins.

Source: | This article originally belongs to Dailymail.co.uk

https://www.soundhealthandlastingwealth.com/health-news/pfizer-announces-two-in-one-vaccine-for-covid-and-flu/ Pfizer announces two-in-one vaccine for Covid AND flu

Brian Ashcraft

TheHiu.com is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@thehiu.com. The content will be deleted within 24 hours.

Related Articles

Back to top button